You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePlatelet Activating Factor
Accession NumberDB02261  (EXPT02559)
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIINot Available
CAS number74389-68-7
WeightAverage: 523.6832
Monoisotopic: 523.363789599
Chemical FormulaC26H54NO7P
InChI KeyInChIKey=HVAUUPRFYPCOCA-AREMUKBSSA-N
InChI
InChI=1S/C26H54NO7P/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-21-31-23-26(34-25(2)28)24-33-35(29,30)32-22-20-27(3,4)5/h26H,6-24H2,1-5H3/t26-/m1/s1
IUPAC Name
(2-{[(2R)-2-(acetyloxy)-3-(hexadecyloxy)propyl phosphonato]oxy}ethyl)trimethylazanium
SMILES
CCCCCCCCCCCCCCCCOC[[email protected]](CO[P@@]([O-])(=O)OCC[N+](C)(C)C)OC(C)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1-alkyl,2-acylglycero-3-phosphocholines. These are glycerophosphocholines that carry exactly one acyl chain attached to the glycerol moiety through an ester linkage at the O2-position, and one alkyl chain attached through an ether linkage at the O1-position.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassGlycerophospholipids
Sub ClassGlycerophosphocholines
Direct Parent1-alkyl,2-acylglycero-3-phosphocholines
Alternative Parents
Substituents
  • 1-alkyl,2-acylglycero-3-phosphocholine
  • Phosphocholine
  • Dialkyl phosphate
  • Glycerol ether
  • Choline
  • Alkyl phosphate
  • Phosphoric acid ester
  • Organic phosphoric acid derivative
  • Organic phosphate
  • Acetate salt
  • Quaternary ammonium salt
  • Carboxylic acid ester
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic zwitterion
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9853
Blood Brain Barrier+0.8739
Caco-2 permeable-0.5288
P-glycoprotein substrateSubstrate0.5468
P-glycoprotein inhibitor INon-inhibitor0.708
P-glycoprotein inhibitor IINon-inhibitor0.8673
Renal organic cation transporterNon-inhibitor0.837
CYP450 2C9 substrateNon-substrate0.8951
CYP450 2D6 substrateNon-substrate0.8167
CYP450 3A4 substrateSubstrate0.5503
CYP450 1A2 substrateNon-inhibitor0.8835
CYP450 2C9 inhibitorNon-inhibitor0.895
CYP450 2D6 inhibitorNon-inhibitor0.9047
CYP450 2C19 inhibitorNon-inhibitor0.8362
CYP450 3A4 inhibitorNon-inhibitor0.7665
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9636
Ames testNon AMES toxic0.6905
CarcinogenicityCarcinogens 0.6219
BiodegradationReady biodegradable0.9563
Rat acute toxicity2.8285 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6381
hERG inhibition (predictor II)Non-inhibitor0.6618
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.000225 mg/mLALOGPS
logP2.71ALOGPS
logP2.01ChemAxon
logS-6.4ALOGPS
pKa (Strongest Acidic)1.86ChemAxon
pKa (Strongest Basic)-4.1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area94.12 Å2ChemAxon
Rotatable Bond Count26ChemAxon
Refractivity151.67 m3·mol-1ChemAxon
Polarizability63.09 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-MSNot Available
References
Synthesis Reference

Aiya Sato, Michihiro Sugano, Kouhei Furuya, Takeshi Oshima, Harumitsu Kuwano, Tadashi Hata, Hideyuki Haruyama, "Platelet activating factor antagonists, named “the phomactins”, their preparation and use." U.S. Patent US5308867, issued October, 1980.

US5308867
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Platelet Activating Factor.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Platelet Activating Factor.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Platelet Activating Factor.
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Platelet Activating Factor.
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Platelet Activating Factor.
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Platelet Activating Factor.
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Platelet Activating Factor.
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Platelet Activating Factor.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Platelet Activating Factor.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Platelet Activating Factor.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Platelet Activating Factor.
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Platelet Activating Factor.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Platelet Activating Factor.
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Platelet Activating Factor.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Platelet Activating Factor.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Platelet Activating Factor.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Platelet Activating Factor.
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Platelet Activating Factor.
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Platelet Activating Factor.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Platelet Activating Factor.
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Platelet Activating Factor.
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Platelet Activating Factor.
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Platelet Activating Factor.
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Platelet Activating Factor.
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Platelet Activating Factor.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Platelet Activating Factor.
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Platelet Activating Factor.
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Platelet Activating Factor.
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Platelet Activating Factor.
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Platelet Activating Factor.
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Platelet Activating Factor.
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Platelet Activating Factor.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Platelet Activating Factor.
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Platelet Activating Factor.
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Platelet Activating Factor.
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Platelet Activating Factor.
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Platelet Activating Factor.
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Platelet Activating Factor.
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Platelet Activating Factor.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Platelet Activating Factor.
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Platelet Activating Factor.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Platelet Activating Factor.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Platelet Activating Factor.
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Platelet Activating Factor.
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Platelet Activating Factor.
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Platelet Activating Factor.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Platelet Activating Factor.
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Platelet Activating Factor.
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Platelet Activating Factor.
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Platelet Activating Factor.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Platelet Activating Factor.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Platelet Activating Factor.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Platelet Activating Factor.
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Platelet Activating Factor.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Platelet Activating Factor.
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Platelet Activating Factor.
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Platelet Activating Factor.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Platelet Activating Factor.
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Platelet Activating Factor.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Platelet Activating Factor.
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Platelet Activating Factor.
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Platelet Activating Factor.
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Platelet Activating Factor.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Platelet Activating Factor.
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Platelet Activating Factor.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Platelet Activating Factor.
EstriolThe serum concentration of Estriol can be decreased when it is combined with Platelet Activating Factor.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Platelet Activating Factor.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Platelet Activating Factor.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Platelet Activating Factor.
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Platelet Activating Factor.
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Platelet Activating Factor.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Platelet Activating Factor.
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Platelet Activating Factor.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Platelet Activating Factor.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Platelet Activating Factor.
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Platelet Activating Factor.
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Platelet Activating Factor.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Platelet Activating Factor.
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Platelet Activating Factor.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Platelet Activating Factor.
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Platelet Activating Factor.
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Platelet Activating Factor.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Platelet Activating Factor.
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Platelet Activating Factor.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Platelet Activating Factor.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Platelet Activating Factor.
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Platelet Activating Factor.
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Platelet Activating Factor.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Platelet Activating Factor.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Platelet Activating Factor.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Platelet Activating Factor.
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Platelet Activating Factor.
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Platelet Activating Factor.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Platelet Activating Factor.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Platelet Activating Factor.
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Platelet Activating Factor.
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Platelet Activating Factor.
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Platelet Activating Factor.
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Platelet Activating Factor.
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Platelet Activating Factor.
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Platelet Activating Factor.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Platelet Activating Factor.
LosartanThe serum concentration of Losartan can be decreased when it is combined with Platelet Activating Factor.
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Platelet Activating Factor.
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Platelet Activating Factor.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Platelet Activating Factor.
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Platelet Activating Factor.
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Platelet Activating Factor.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Platelet Activating Factor.
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Platelet Activating Factor.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Platelet Activating Factor.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Platelet Activating Factor.
NadololThe serum concentration of Nadolol can be decreased when it is combined with Platelet Activating Factor.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Platelet Activating Factor.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Platelet Activating Factor.
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Platelet Activating Factor.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Platelet Activating Factor.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Platelet Activating Factor.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Platelet Activating Factor.
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Platelet Activating Factor.
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Platelet Activating Factor.
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Platelet Activating Factor.
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Platelet Activating Factor.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Platelet Activating Factor.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Platelet Activating Factor.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Platelet Activating Factor.
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Platelet Activating Factor.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Platelet Activating Factor.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Platelet Activating Factor.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Platelet Activating Factor.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Platelet Activating Factor.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Platelet Activating Factor.
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Platelet Activating Factor.
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Platelet Activating Factor.
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Platelet Activating Factor.
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Platelet Activating Factor.
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Platelet Activating Factor.
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Platelet Activating Factor.
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Platelet Activating Factor.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Platelet Activating Factor.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Platelet Activating Factor.
ReserpineThe serum concentration of Reserpine can be decreased when it is combined with Platelet Activating Factor.
RifampicinThe serum concentration of Rifampicin can be decreased when it is combined with Platelet Activating Factor.
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Platelet Activating Factor.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Platelet Activating Factor.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Platelet Activating Factor.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Platelet Activating Factor.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Platelet Activating Factor.
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Platelet Activating Factor.
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Platelet Activating Factor.
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Platelet Activating Factor.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Platelet Activating Factor.
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Platelet Activating Factor.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Platelet Activating Factor.
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Platelet Activating Factor.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Platelet Activating Factor.
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Platelet Activating Factor.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Platelet Activating Factor.
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Platelet Activating Factor.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Platelet Activating Factor.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Platelet Activating Factor.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Platelet Activating Factor.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Platelet Activating Factor.
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Platelet Activating Factor.
TimololThe serum concentration of Timolol can be decreased when it is combined with Platelet Activating Factor.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Platelet Activating Factor.
TopotecanThe serum concentration of Topotecan can be decreased when it is combined with Platelet Activating Factor.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Platelet Activating Factor.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Platelet Activating Factor.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Platelet Activating Factor.
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Platelet Activating Factor.
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Platelet Activating Factor.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Platelet Activating Factor.
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Platelet Activating Factor.
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Platelet Activating Factor.
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Platelet Activating Factor.
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Platelet Activating Factor.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Platelet Activating Factor.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Phospholipase activator activity
Specific Function:
The large binding pocket can accommodate several single chain phospholipids and fatty acids, GM2A also exhibits some calcium-independent phospholipase activity (By similarity). Binds gangliosides and stimulates ganglioside GM2 degradation. It stimulates only the breakdown of ganglioside GM2 and glycolipid GA2 by beta-hexosaminidase A. It extracts single GM2 molecules from membranes and presents...
Gene Name:
GM2A
Uniprot ID:
P17900
Molecular Weight:
20838.1 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23